Platelet-rich plasma effective remedy for dry eye

Article

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Jorge Alio and colleagues from the Instituto Oftalmologico de Alicante and the Universidad Migul Hernandez, Alicante, Spain, treated 18 consecutive dry eye patients with topical PRP. The researchers were looking for the disappearance of subjective symptoms, increases in best corrected visual acuity (BCVA), tear meniscus, tear break-up time and decreases in inflammation and fluorescein staining. Improvements in impression cytology were also measured.

At one-month follow-up, 89% of subjects demonstrated a significant improvement in symptoms and 28% improved by at least one line of BCVA. A significant improvement in lachrymal meniscus and conjunctival hyperaemia, and a decrease or disappearance of corneal fluorescein staining was observed. Meanwhile, impression cytology revealed a significant increase in conjunctival goblet cells.

The authors of the study conclude that autologous PRP is a very effective treatment for severe dry eye symptoms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.